Evidence from Biomarkers and Surrogate Endpoints

AUTOR(ES)

Feigin, Andrew

FONTE

The American Society for Experimental NeuroTherapeutics

RESUMO

Summary: The use of physiological, anatomical, and other biological tests is commonplace in the practice of medicine. In neurology, objectively measured tests termed biomarkers (BMs) are playing an increasing role in diagnosis and management of disease, both in clinical practice and in experimental therapeutics. This article will discuss the various applications of BMs to the assessment of therapies for neurological diseases and will use examples from neurological diseases to elucidate the strengths and potential weaknesses of BMs. As the understanding of the pathophysiology of many neurological diseases has improved, new BMs have been developed, and efforts have been made to use these as proxies for clinical endpoints. A BM used in this manner is referred to as a surrogate endpoint (SE). There are many potential advantages and disadvantages of using SEs in the evaluation of new therapies, and these will be reviewed as well. Furthermore, the evidence required for the development of an SE and the nature of the evidence that can be derived from the use of BMs and SEs will be discussed.

Documentos Relacionados

• A winter’s tale: Report from the First Annual Canadian Biomarkers and Surrogate Endpoints Symposium
• Biomarkers and Surrogate Outcomes in Neurodegenerative Disease: Lessons from Multiple Sclerosis
• Biomarkers and Surrogate Markers: An FDA Perspective
• Biomarkers and Surrogates
• Palindromy and the Location of Deletion Endpoints in Escherichia Coli